Johns Hopkins University School of Medicine Baltimore, Maryland
Director, Department of Cell Biology Professor of Cell Biology Professor of Biomedical Engineering Professor of Oncology and Co-Director, Cancer Invasion and Metastasis Program Sidney Kimmel Comprehensive Cancer Center
Understanding how breast cancer spreads and identifying preventive strategies to improve patient outcomes.
The major cause of breast cancer deaths is metastasis, the process by which breast cancer cells invade distant organs and establish new tumors there. To prevent this process from occurring, researchers must first identify the mechanisms that drive it. Dr. Ewald is studying metastasis at the cellular and molecular level with the goal of discovering ways to both prevent and treat metastatic breast cancer (MBC). His findings may guide the development of new strategies to improve outcomes for women with MBC.
Metastasis requires cancer cells to accomplish many different tasks: escaping the primary tumor, entering, and surviving within blood vessels, evading immune cells, and growing in an unfamiliar organ. To succeed, cancer cells must first break free from the tumor and then they must survive as they travel through the body. The main lesson Dr. Ewald has learned from his BCRF-funded research is that the most dangerous cancer cells are the ones that are the most flexible—those that can rapidly change their structure and function to accomplish each successive task in metastasis.
Dr. Ewald and his team have uncovered the roles of proteins in two molecular complexes that maintain tissue connectivity: the tight junction and the adherens junction. Both structures enable strong connections among cells but have very different roles. The protein Claudin 7 in the tight junction is a natural defense against metastasis and its loss makes cancer cells more metastatic, while loss of the key protein of the adherens junction, E-cadherin, surprisingly made cancer cells less metastatic because the cancer cells rapidly died. The team demonstrated that this is because half of E-cadherin mediates adhesion and suppresses invasion while the other half promotes cell survival. The different halves can play different roles because specific enzymes can cleave the protein into different pieces that function in different parts of the cell. These discoveries may represent new strategies to target the molecular pathways driving metastasis.
In the coming year, Dr. Ewald will utilize genetic and molecular techniques to identify exactly which parts of E-cadherin accomplish these different functions and where they occur within the cancer cells. Together, these experiments will define the molecular interactions among cancer cells that alternatively resist and promote metastasis. Dr. Ewald’s goal is to apply these insights to target the molecular vulnerabilities of metastatic breast cancer cells.
Andrew J. Ewald earned his BS in physics from Haverford College and his PhD in biochemistry and molecular biophysics from the California Institute of Technology. He is a professor in the Departments of Cell Biology, Oncology, and Biomedical Engineering at the Johns Hopkins University School of Medicine. His laboratory has pioneered the use of 3D culture techniques to study the growth and invasion of breast cancer cells.
Dr. Ewald’s goal is to identify the molecules driving metastatic spread to enable the development of targeted therapies. His laboratory includes basic science and medical trainees and he collaborates with both engineers and clinicians. BCRF funding is critical to his current efforts to develop strategies to identify the patients at highest risk of metastatic recurrence and to develop innovative therapies to treat patients with metastatic breast cancer.
Dr. Ewald founded the Cancer Invasion and Metastasis Research Program at the Sidney Kimmel Comprehensive Cancer Center, which brings together 40 faculty from 15 departments to understand how metastasis works and bring these insights to patient benefit. In 2021, he was appointed director of the Department of Cell Biology at Johns Hopkins Medicine. His department has historic strengths in imaging, cell migration, lipid trafficking, and cancer cell biology. Leadership of these two units enables him to bring together basic scientists, engineers, and clinicians and to apply cutting edge technologies and multidisciplinary perspectives to solve problems in breast cancer
2013
The Play for P.I.N.K. Award
Please remember BCRF in your will planning. Learn More
